If you have an oncology condition you may be eligible to participate in a patient clinical trial for the condition.

The team here at Scientia Clinical Research would love to welcome you on a clinical trial, but first you will need a medical referral letter including all relevant treatment and diagnostic information. You may also speak to your oncology consultant, and they will be able to contact us if you are a suitable candidate for referral.

To facilitate prompt review of referral, please include the following:

  • A clinical trial referral letter
  • Medical and treatment history
  • Most recent blood test and scan results
  • Histopathology or biopsy reports
  • Molecular pathology result, if available
  • Contact details of referring doctor

If you have have any questions please email our team at : ContactUs@scientiaclinicalresearch.com.au

SR-8541A-001

This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A, an ENPP1 inhibitor

Location

Randwick, Sydney

Category

Advanced Metastatic Solid Tumours

Open for recruitment
More Info

BL0020-101

A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients with Advanced Solid Tumors

Location

Randwick, Sydney

Category

Advanced Solid Tumours
Open for recruitment
More Info

CIBI130A101

A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors

Location

Randwick, Sydney

Category

Metastatic Solid Tumours
Open for recruitment
More Info

ES009-1001

An Open-Label, Multicenter, First-in-Human, Phase 1 Study of ES009 in Subjects with Locally Advanced or Metastatic Solid Tumors

Location

Randwick, Sydney

Category

Metastatic Solid Tumours
Open for recruitment
More Info

DCSZ11-101

A Phase 1, Multicenter, Open-label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumour Activity of DCSZ11 as a Monotherapy in Patients with Advanced or metastatic Solid Tumours 

Location

Randwick, Sydney

Category

Advanced Solid Tumours
Open for recruitment
More Info

IMC-F106C-101

A Phase 1 / 2 First-in-human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01- Positive Participants with Advanced PRAME-Positive Cancers

Location

Randwick, Sydney

Category

Advanced Positive Cancers

Open for recruitment
More Info

IMM47-201

A Phase 1, Open-Label, Multicenter, Dose-Escalation and Cohort-Expansion Study of IMM47 in Subjects with Advanced Solid Tumours

Location

Randwick, Sydney

Category

Advanced Solid Tumours

Open for recruitment
More Info

DB-1311-0-1001

A Phase 1/2a, multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumours.

Location

Randwick, Sydney

Category

Advanced Solid Tumours
Open for recruitment
More Info

MTX-TROP2-302

A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmcodynamics and Preliminary Efficacy of MT-302 in Adults with Advanced or Metastatic Epithelial Tumors.

Location

Randwick, Sydney

Category

Advanced Solid Tumours
Open for recruitment
More Info

SHR-A1921-I-102-AUS

An open-label, multi-center phase in clinical study on the safety, tolerability, pharmacokinetics, and clinical activity of SHR-A1921 for injection in subjects with advanced solid tumours

Location

Randwick, Sydney

Category

Advanced Solid Tumours

Open for recruitment
More Info

ATG-101-001

A First-in-Human Phase I Trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas. “PROBE Study”

Location

Randwick, Sydney

Category

Advanced Solid Tumours and Mature B-cell NHL

Open for recruitment
More Info

MDNA11-01

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors. “ABILITY Study”

Location

Randwick, Sydney

Category

Advanced Solid Tumours

Open for recruitment
More Info

SHR-2002-102

A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors

Location

Randwick, Sydney

Category

Advanced Solid Tumours

Open for recruitment
More Info

CS5001-101

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas

Location

Randwick, Sydney

Category

Advanced Solid Tumours and Lymphomas

Open for recruitment
More Info

CP-MVC-101-01

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer

Location

Randwick, Sydney

Category

Unresectable Locally Advanced or Metastatic Cancer

Open for recruitment
More Info

SHR-A1904-I-104

AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS EXPRESSING CLAUDIN 18.2

Location

Randwick, Sydney

Category

Advanced Solid Tumours

Open for recruitment
More Info

80948543LYM1001

A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL

Location

Randwick, Sydney

Category

Advanced Solid Tumours

Open for recruitment
More Info

AMX-818-001

A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of AMX-818 Alone and in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic HER2-Expressing Cancers

Location

Randwick, Sydney

Category

Locally Advanced or Metastatic HER2-Expressing Cancers

Open for recruitment
More Info

AXA-042-FIH-01

A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumors.

Location

Randwick, Sydney

Category

Advanced Solid Tumours

Open for recruitment
More Info

SHR-A1921-I-102

AN OPEN-LABEL, MULTI-CENTER PHASE I CLINICAL STUDY ON THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND CLINICAL ACTIVITY OF SHR-A1921 FOR INJECTION IN SUBJECTS WITH ADVANCED SOLID TUMORS

Location

Randwick, Sydney

Category

Advanced Solid Tumours

Open for recruitment
More Info

CIBI354A101

A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Location

Randwick, Sydney

Category

Locally Advanced Unresectable or Metastatic Solid Tumors

Open for recruitment
More Info

THOR-707-101

An open-label, multicenter Phase 1/2 dose escalation and expansion study of THOR-707 as a Single agent and as a combination therapy in adult subjects with advanced or metastatic solid tumors

Location

Randwick, Sydney

Category

advanced or metastatic solid tumors

Open for recruitment
More Info

ATG-017-001

A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017.

Monotherapy or Combination Therapy with Nivolumab in Patients with Advanced Solid Tumours and Haematological Malignancies

Location

Randwick, Sydney

Category

Advanced solid tumors

Open for recruitment
More Info

We also conduct Healthy Volunteer Clinical trials which may be of interest for people with no medical conditions.